Long-Acting Monoclonal Antibodies Market Estimations (2025 - 2035)
The long-acting monoclonal antibodies market covers monoclonal antibodies engineered for extended half-life, including FcRn-affinity (YTE-type) mutations and pH-dependent recycling designs, such as ravulizumab, nirsevimab, clesrovimab, depemokimab, satralizumab and crovalimab, dosed every four weeks to once per season or twice a year, given intravenously, intramuscularly or subcutaneously, for complement-mediated and rare diseases, RSV and other infection prevention and respiratory and type 2 inflammatory disease.